CD274 and lung carcinoma: In lung cancer, PD-L1 expression on tumor tissue, defined by immunohistochemistry and tumor mutational burden, based on whole exome sequencing analysis, are the only two positive biomarkers for the response to anti PD-1/PD-L1 immunotherapy, while variants in EGFR and STK11 genes were found to be associated, with no benefit in NSCLC patients [74,75,76].